These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 21725844)
1. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Erb C; Lanzl I; Seidova SF; Kimmich F Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844 [TBL] [Abstract][Full Text] [Related]
2. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Hommer A; Mohammed Ramez O; Burchert M; Kimmich F Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122 [TBL] [Abstract][Full Text] [Related]
3. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237 [TBL] [Abstract][Full Text] [Related]
4. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients. Rossi GC; Pasinetti GM; Raimondi M; Ricciardelli G; Scudeller L; Blini M; Amisano A; Bianchi PE Expert Opin Drug Saf; 2012 Jul; 11(4):519-25. PubMed ID: 22690824 [TBL] [Abstract][Full Text] [Related]
6. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371 [TBL] [Abstract][Full Text] [Related]
7. Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study. Pillunat LE; Erb C; Ropo A; Kimmich F; Pfeiffer N Clin Ophthalmol; 2017; 11():1051-1064. PubMed ID: 28652689 [TBL] [Abstract][Full Text] [Related]
8. [Efficacy and tolerability of preservative-free tafluprost 0.0015 % in the treatment of glaucoma and ocular hypertension]. Karhanová M; Mlčák P; Fryšák Z; Marešová K Cesk Slov Oftalmol; 2012 Oct; 68(4):150-5. PubMed ID: 23214487 [TBL] [Abstract][Full Text] [Related]
9. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components. Pfeiffer N; Traverso CE; Lorenz K; Saarela V; Liinamaa J; Uusitalo H; Astakhov Y; Boiko E; Ropo A; Adv Ther; 2014 Dec; 31(12):1228-46. PubMed ID: 25447269 [TBL] [Abstract][Full Text] [Related]
10. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension. Swymer C; Neville MW Ann Pharmacother; 2012 Nov; 46(11):1506-10. PubMed ID: 23092867 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Hamacher T; Airaksinen J; Saarela V; Liinamaa MJ; Richter U; Ropo A Acta Ophthalmol Suppl (Oxf ); 2008; 242():14-9. PubMed ID: 18752510 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Uusitalo H; Pillunat LE; Ropo A; Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586 [TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]. Trinquand C; Romanet JP; Nordmann JP; Allaire C; J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585 [TBL] [Abstract][Full Text] [Related]
14. Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension. Lanzl I; Hamacher T; Rosbach K; Ramez MO; Rothe R; Růžičková E; Karhanová M; Kimmich F Clin Ophthalmol; 2013; 7():901-10. PubMed ID: 23717036 [TBL] [Abstract][Full Text] [Related]
15. Spanish multicenter tafluprost tolerability study. Milla E; Stirbu O; Rey A; Duch S; Buchacra O; Robles A; Navarro C; Gil R; Cordero JM Br J Ophthalmol; 2012 Jun; 96(6):826-31. PubMed ID: 22399693 [TBL] [Abstract][Full Text] [Related]
16. Preservative-Free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% for Treatment-Naive Patients with Open-Angle Glaucoma. Rhee T; Kim J; Ha A Korean J Ophthalmol; 2024 Jun; 38(3):221-226. PubMed ID: 38665112 [TBL] [Abstract][Full Text] [Related]
17. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain. Garcia-Medina JJ; Benitez-Del-Castillo J; Rodríguez-Agirretxe I; Lopez-Lopez F; Moreno-Valladares A; J Ocul Pharmacol Ther; 2022 Apr; 38(3):252-260. PubMed ID: 35230148 [No Abstract] [Full Text] [Related]
18. Tafluprost: a novel prostaglandin analog for treatment of glaucoma. Pantcheva MB; Seibold LK; Awadallah NS; Kahook MY Adv Ther; 2011 Sep; 28(9):707-15. PubMed ID: 21858491 [TBL] [Abstract][Full Text] [Related]
19. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Kuwayama Y; Nomura A Adv Ther; 2014 Apr; 31(4):461-71. PubMed ID: 24615289 [TBL] [Abstract][Full Text] [Related]
20. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study. Oddone F; Tanga L; Kóthy P; Holló G; Adv Ther; 2020 Apr; 37(4):1436-1451. PubMed ID: 32072493 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]